Latest Disease-modifying antirheumatic drug Stories
WALTHAM, Mass., Nov.
More studies that directly compare the effectiveness of different biologic drugs for rheumatoid arthritis (RA) are needed, say Cochrane Researchers.
MAIDENHEAD, England, September 22 /PRNewswire/ -- - 26 Men and Women With RA From Across Europe Honoured as They Share Their Inspirational Stories Actress, artist and activist Jane Seymour will host the first My Day for RA European event in Barcelona, Spain this evening to recognise the daily challenges, hopes and achievements of people living with rheumatoid arthritis (RA). To view the Multimedia News Release, please click: http://www.prnewswire.com/mnr/wyeth/40154/...
WILMINGTON, Delaware, September 1 /PRNewswire/ -- According to a new market research report, 'Global Autoimmune Treatment Market (2009-2014)', published by MarketsandMarkets ( http://www.marketsandmarkets.com), the global autoimmune treatment market is expected to be worth US$68.81 billion by 2014, with an estimated CAGR of 12.7% from 2009 to 2014.
A quarter of active rheumatoid arthritis (RA) patients receiving either 10mg (24.6%) or 15mg (28.1%) twice daily of the investigational oral JAK-3 (janus-associated kinase) inhibitor CP-690,550 (CP) achieved ACR70* after 12 weeks, according to the results of a new study presented today at EULAR 2009
- Additional data reinforce long-term efficacy of ACTEMRA across a broad range of rheumatoid arthritis patient populations - NUTLEY, N.J., June 9 /PRNewswire/ -- One-year data from the two-year Phase III LITHE (TociLIzumab Safety and THE Prevention of Structural Joint Damage) study demonstrated that a greater proportion of rheumatoid arthritis (RA) patients treated with ACTEMRA(R) (tocilizumab), a novel interleukin-6 (IL-6) receptor inhibitor, in combination with methotrexate, experienced a...
- Results of Phase III clinical studies highlight benefits of ACTEMRA as a treatment for rheumatoid arthritis - NUTLEY, N.J., June 4 /PRNewswire/ -- Roche today announced that oral and poster presentations highlighting results from the extensive multi-national ACTEMRA(R) (tocilizumab) clinical development program will be presented at the 10th Annual Congress of the European League Against Rheumatism (EULAR), which will take place June 10-13, 2009, in Copenhagen, Denmark.
Rheumatoid arthritis (RA), the most common form of inflammatory arthritis, affects almost three percent of people over age 65. RA patients experience pain, functional limitations and two forms of disabling bone disease: focal erosions and osteoporosis.
Biologic disease-modifying antirheumatic drugs (DMARDs) such as adalimumab, etanercept and infliximab are effective at reducing symptoms and slowing progression of rheumatoid arthritis (RA).
TAIPEI, Taiwan, April 10 /PRNewswire/ -- Rheumatoid arthritis (RA) is a systemic disease or an autoimmune disorder in which the body's defense system attacks the joints through the thin layer of cells called the synovium that lines and lubricates the joints.
- The parings of haberdine; also, any kind of fragments.